Journal profile · ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
OncoImmunology
ISSN 2162-402X · Landes Bioscience · UNITED STATES
OncoImmunology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.16; JCR Q1 (journal website); fully open access; APC about USD 3,300; median 123 days to acceptance (98 articles, last 24 months); acceptance rate 11% (journal website); 120 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
OncoImmunology is published by Landes Bioscience and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and Immune Cell Function and Interaction, together about 51.3% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
OncoImmunology is a dynamic, high-profile, open access journal broadly covering tumor immunology and immunotherapy. As cancer immunotherapy continues to evolve, OncoImmunology aims to publish high-quality, rigorous research on all aspects of basic and applied tumor immunology. Topics covered include: Basic and translational studies in immunology of both solid and hematological malignancies Inflammation, innate and acquired immune responses against cancer Mechanisms of cancer immunoediting and immune evasion Modern immunotherapies including, but not limited to, immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell and macrophage engagers, and CAR T cells Immunological effects of conventional anticancer therapies. The journal publishes Research Articles, Review Articles, Brief Reports, Trial Watches, Article Commentaries, and Editorials. Please note that Trial Watches are solicited by the Editors on an invitation-only basis. The journal does not accept case reports or bibliometric analyses. OncoImmunology operates a single-anonymized peer review policy.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
Editor-in-chief Lorenzo GalluzziPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine18.6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology17.4%
- Immune Cell Function and InteractionImmunology and Microbiology15.3%
- CAR-T cell therapy researchMedicine11.2%
- Immune cells in cancerImmunology and Microbiology7.8%
- T-cell and B-cell ImmunologyImmunology and Microbiology5.7%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology2.2%
- Monoclonal and Polyclonal Antibodies ResearchMedicine2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCEmbasePublisher website
Other: EBSCOhost, Biological Abstracts (Online), Biomedical Reference Collection: Corporate Edition, Elsevier BV, National Library of Medicine, Thomson Reuters, BIOSIS Previews
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.16LetPub ·
- Impact factor (publisher) 2025
- 6.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 6.5Publisher website ·
- CiteScore 2026-06
- 12.1LetPub ·
- CiteScore (publisher) 2025
- 12.1Publisher website ·
- SJR 2026-06
- 2.44LetPub ·
- SJR (publisher) 2025
- 2.44Publisher website ·
- SNIP 2026-06
- 1.1LetPub ·
- SNIP (publisher) 2025
- 1.1Publisher website ·
- h-index
- 49LetPub ·
- h-index
- 154OpenAlex ·
- i10-index
- 3,025OpenAlex ·
- 2-year mean citedness
- 6.4OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 116LetPub ·
- Downloads per year (publisher)
- 1,600,000Publisher website ·
Articles by year OpenAlex count · 3,918 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 84 | 84 | 64 |
| 2025 | 120 | 120 | 682 |
| 2024 | 119 | 119 | 1,320 |
| 2023 | 129 | 129 | 2,186 |
| 2022 | 194 | 194 | 5,674 |
| 2021 | 234 | 234 | 8,062 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
123 daysMedian, submission to acceptance · P25–P75 71 days – 184 days
- Acceptance to online
- median 11 days (98 articles)
- Submission to online
- median 143 days
- Sample
- 98 articles with submission and acceptance dates (238 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 24 weeksLetPub ·
- Acceptance rate (publisher)
- 11%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 46 daysPublisher website ·
- Acceptance to publication
- 11 daysPublisher website ·
- Submission to publication (journal-reported)
- about 24 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,300 / GBP 2,640 / EUR 3,170 / AUD 4,595 | Yes | CC BY, CC BY-NC | |
| OpenAlex | GBP 2,375 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Not considered
- case reports; bibliometric analyses
Article types accepted6
- article commentariesThe journal publishes Research Articles, Review Articles, Brief Reports, Trial Watches, Article Commentaries, and Editorials.Length not stated
- brief reportsThe journal publishes Research Articles, Review Articles, Brief Reports, Trial Watches, Article Commentaries, and Editorials.Length not stated
- editorialsThe journal publishes Research Articles, Review Articles, Brief Reports, Trial Watches, Article Commentaries, and Editorials.Length not stated
- research articlesThe journal publishes Research Articles, Review Articles, Brief Reports, Trial Watches, Article Commentaries, and Editorials.Length not stated
- review articlesThe journal publishes Research Articles, Review Articles, Brief Reports, Trial Watches, Article Commentaries, and Editorials.Length not stated
- trial watchesThe journal publishes Research Articles, Review Articles, Brief Reports, Trial Watches, Article Commentaries, and Editorials. Please note that Trial Watches are…Length not stated
Policy excerpts from the journal's websiteAuthorship, Open access, Peer review
- Authorship
Does not accept case reports or bibliometric analyses Model summary
The journal does not accept case reports or bibliometric analyses.
Source ↗Publisher website ·- Open access Open access
Open access journal Model summary
OncoImmunology is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just those with eas…
Source ↗Publisher website ·- Peer review
Single-anonymized peer review Model summary
OncoImmunology operates a single-anonymized peer review policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Landes Bioscience
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2162-402X
- Latest issue on the website
- Volume 15, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about OncoImmunology
What CAS zone is OncoImmunology in?
In the 2025 upgraded edition of the CAS Journal Ranking, OncoImmunology is in Zone 2 of Medicine, and in Zone 2 of the minor category Immunology / Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of OncoImmunology?
The latest impact factor listed by LetPub is 6.16; CiteScore 12.1, h-index 154.
How long does peer review take at OncoImmunology?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 123 days (interquartile range 71–184 days); authors report an average review time of about 24 weeks; the journal's website gives an acceptance rate of 11%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is OncoImmunology in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Medicine.
Which databases index OncoImmunology?
According to LetPub and DOAJ records, OncoImmunology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, PMC and Embase; that list has not been checked against each database.
Is OncoImmunology open access, and what is the APC?
OncoImmunology is a fully open-access journal. APC about USD 3,300.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .